» Articles » PMID: 24888404

Diabetic Peripheral Neuropathy: Resource Utilization and Burden of Illness

Overview
Journal J Med Econ
Date 2014 Jun 4
PMID 24888404
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes and accounts for significant morbidity by pre-disposing the foot to ulceration and lower extremity amputation. Using a large US commercial claims database, this study analyzes the drug class usage and co-morbidities associated with DPN as well as estimates the associated economic burden.

Methods: Patients older than 18 and diagnosed with DPN were followed longitudinally for 2 years pre- and post-diagnosis date. Patients were analyzed for age, gender, hospital visits, ER and doctor's office visits, pharmacy claims, co-morbidities, and drug classes prescribed pre- and post-DPN diagnosis. The economic impact post-diagnosis of DPN was compared to the patients' pre-diagnosis resource use.

Results: In total, 10,982 incident DPN patients were identified, with a median age of 61 years, and an equal gender distribution. Post-DPN diagnosis, there was a 20% increase in the number of patients visiting hospitals and a 46% increase in the number of visits to hospitals. Further, there was a 46% increase in the annual cost per patient associated with visits to the hospitals, emergency room (ER), doctor's office, and pharmacy claims. As per the analysis presented in this study, increase in the number of visits, cost per visit, and number of patients visiting hospitals, ER and doctor's offices added up to a 46% increase in aggregated cost associated with Medical Resource Utilization (MRU) owing to DPN, with the highest increase (60%) in costs associated with hospitalization of patients with DPN.

Conclusion: This study highlights the high economic burden associated with DPN. The results indicate that resource use significantly increases post-diagnosis of DPN, which leads to an increase in costs for payers. A noticeable proportion of patients with DPN had a pain co-diagnosis signifying the need for treatments that can effectively manage painful DPN.

Citing Articles

The global and regional burden of diabetic peripheral neuropathy.

Savelieff M, Elafros M, Viswanathan V, Jensen T, Bennett D, Feldman E Nat Rev Neurol. 2024; 21(1):17-31.

PMID: 39639140 DOI: 10.1038/s41582-024-01041-y.


The accuracy of 10 g monofilament use for clinical screening of diabetes peripheral neuropathy among Indian population.

Hazari A, Mishra V, Kumar P, Maiya A PLoS One. 2024; 19(2):e0297110.

PMID: 38394307 PMC: 10890773. DOI: 10.1371/journal.pone.0297110.


Sciatic nerve fractional anisotropy and neurofilament light chain protein are related to sensorimotor deficit of the upper and lower limbs in patients with type 2 diabetes.

Kender Z, Jende J, Kurz F, Tsilingiris D, Schimpfle L, Sulaj A Front Endocrinol (Lausanne). 2023; 14:1046690.

PMID: 37008917 PMC: 10053786. DOI: 10.3389/fendo.2023.1046690.


Scores of peripheral neuropathic pain predicting long-term mortality in patients with type 2 diabetes: A retrospective cohort study.

Liau Y, Lin S, Lee I Front Endocrinol (Lausanne). 2022; 13:969149.

PMID: 36051389 PMC: 9424503. DOI: 10.3389/fendo.2022.969149.


Vibrotactile perception on the sole of the foot in an older group of people with normal glucose tolerance and type 2 diabetes.

Peterson M, Pingel R, Rolandsson O, Dahlin L SAGE Open Med. 2020; 8:2050312120931640.

PMID: 32587694 PMC: 7294473. DOI: 10.1177/2050312120931640.